BIOMAT Database Logo BIOMAT Database Logo

A novel peptide shows excellent anti-HIV-1 potency as a gp41 fusion inhibitor. 2018

Wei Liu, and Xiaohong An, and Jiao Wang, and Xiaoguang Zhang, and Jianjun Tan, and Zhixiang Zhou, and Yi Zeng
College of Life Science and Bioengineering, Beijing University of Technology, Beijing 100124, China; State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing 100052, China.

Fusion inhibitors of HIV prevent the virus from entering into the target cell via the interaction with gp41, which stops the process of spatial rearrangement of the viral envelope protein. A series of peptides have been designed and screened to obtain a highly potent novel sequence. Among them, CT105 possesses the most potent anti-viral ability at low nanomolar IC50 values against a panel of HIV-1 pseudoviruses from A, B, C and A1/D subtypes, whereas T20 shows much weaker potency. CT105 also shows excellent inhibitory activity at 260 pico molar IC50 against HIV-1 replication. As a fusion inhibitor, CT105 has a strong ability to interrupt gp41 core formation. The terminal half-life of CT105 possesses 1.72-fold longer than that of T20 as determined by developing an indirect competitive ELISA method. The results suggest that this artificial peptide CT105 could be a favorable architype for further optimization and modification.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015700 HIV Envelope Protein gp41 Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING. Envelope Protein gp41, HIV,HIV Transmembrane Protein gp41,HTLV-III gp41,env Protein gp41, HIV,gp41(HIV),gp41 Envelope Protein, HIV
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Wei Liu, and Xiaohong An, and Jiao Wang, and Xiaoguang Zhang, and Jianjun Tan, and Zhixiang Zhou, and Yi Zeng
A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability.
August 2011, The Journal of biological chemistry,
Wei Liu, and Xiaohong An, and Jiao Wang, and Xiaoguang Zhang, and Jianjun Tan, and Zhixiang Zhou, and Yi Zeng
A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41.
December 2016, Amino acids,
Wei Liu, and Xiaohong An, and Jiao Wang, and Xiaoguang Zhang, and Jianjun Tan, and Zhixiang Zhou, and Yi Zeng
Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
April 2007, Cell,
Wei Liu, and Xiaohong An, and Jiao Wang, and Xiaoguang Zhang, and Jianjun Tan, and Zhixiang Zhou, and Yi Zeng
A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
February 2012, ChemMedChem,
Wei Liu, and Xiaohong An, and Jiao Wang, and Xiaoguang Zhang, and Jianjun Tan, and Zhixiang Zhou, and Yi Zeng
Thermodynamics of peptide inhibitor binding to HIV-1 gp41.
May 2001, Biochemistry,
Wei Liu, and Xiaohong An, and Jiao Wang, and Xiaoguang Zhang, and Jianjun Tan, and Zhixiang Zhou, and Yi Zeng
Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
April 2007, Biochemistry,
Wei Liu, and Xiaohong An, and Jiao Wang, and Xiaoguang Zhang, and Jianjun Tan, and Zhixiang Zhou, and Yi Zeng
Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.
July 2012, Virology,
Wei Liu, and Xiaohong An, and Jiao Wang, and Xiaoguang Zhang, and Jianjun Tan, and Zhixiang Zhou, and Yi Zeng
Design, synthesis and activity evaluation of novel peptide fusion inhibitors targeting HIV-1 gp41.
January 2016, Bioorganic & medicinal chemistry,
Wei Liu, and Xiaohong An, and Jiao Wang, and Xiaoguang Zhang, and Jianjun Tan, and Zhixiang Zhou, and Yi Zeng
A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion.
November 1993, AIDS research and human retroviruses,
Wei Liu, and Xiaohong An, and Jiao Wang, and Xiaoguang Zhang, and Jianjun Tan, and Zhixiang Zhou, and Yi Zeng
Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.
November 2009, PLoS pathogens,
Copied contents to your clipboard!